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S U M M A R Y
Objectives: Immune regulatory mechanisms may limit the immunopathologic condition of infection
with Mycobacterium tuberculosis and suppress cellular immune responses in the host. We investigated
the CD4+CD25+FoxP3+ circulating regulatory T cells (Treg) in patients with cavity multidrug-resistant
tuberculosis (MDR-TB) before and after surgery.
Methods: We compared the proportion of Treg cells in 13 patients with cavity MDR-TB pre- and
postoperatively and in 10 healthy control subjects by ﬂow cytometry using three speciﬁc markers in
peripheral blood lymphocytes: cell-surface CD4 and CD25 expression and intracellular FoxP3
expression.
Results: The proportion of CD4+CD25high and CD4+CD25+FoxP3+ Treg was signiﬁcantly higher in patients
with cavityMDR-TB and at 1-month postoperatively than in healthy controls (p < 0.001). The proportion
of CD4+ and CD4+CD25 cells was signiﬁcantly lower in patients with cavity MDR-TB than in controls
(p < 0.001). Pre- and postoperative proportions of CD4+CD25high and CD4+CD25+FoxP3+ Treg cells
showed a positive correlation (r = 0.878, p < 0.001).
Conclusion: Circulating Treg cells are increased in proportion in patients with cavity MDR-TB and
decreased after surgery. Infection with M. tuberculosis may induce Treg cell-surface molecular changes
with increased numbers of cells.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Tuberculosis (TB) is associated with chronic, persistent antigen
stimulation in vivo to maintain a sustained immune response,
which suppresses but generally fails to eradicate Mycobacterium
tuberculosis (MTB) infection.Worldwide, an estimated 9.27million
cases of TB occurred in 2007.1 Strains of M. tuberculosis that are
resistant to both isoniazid and rifampin with or without resistance
to other drugs have been termedmultidrug-resistant TB (MDR-TB).
Drug resistance information from 114 countries and the two
special administrative regions (SARs) of China (i.e., Hong Kong and
Macau), combined with nine epidemiological factors, revealed the
global proportion of MDR-TB among new and previously treated
cases to be 4.8% (95% conﬁdence interval 4.6–6.0%). China and
India carry approximately 50% of the global burden of disease.2 The
proportion of MDR-TB is higher than before, but the reasons are* Corresponding author. Tel.: +86 754 88900445; fax: +86 754 88557562.
E-mail address: ke_li88@yahoo.cn (K. Li).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.04.005unclear. Host genetic factorsmay contribute to the development of
MDR-TB, and incomplete and inadequate treatment is the most
important factor leading to its development. MDR-TB is difﬁcult to
control by medical therapy alone, and surgery has emerged as a
therapeutic option.3,4
CD4+ and CD8+ T-cell-mediated immunity is the main protec-
tion against TB.5 CD4+ regulatory T cells (Treg cells) play a key role
in the control of the immune system. The most commonly used
marker for Treg cells is CD25 (interleukin 2 (IL-2) receptor a),
6
although the recently identiﬁed transcription factor FoxP3 is more
speciﬁc.7 The suppression function of FoxP3 mRNA expression is
mediated via direct cell–cell contact or the secretion of interleukin
10 (IL-10) or transforming growth factor beta (TGF-b).8 The
proportion of CD4+CD25high T cells and levels of FoxP3 mRNA
expression have both been found to be signiﬁcantly higher in
peripheral blood mononuclear cells (PBMCs) of patients with TB
than in cells of healthy controls.9 Also, the proportion of
CD4+CD25high T cells and level of CD4+CD25high FoxP3 mRNA
have been found to be signiﬁcantly higher in PBMCs of patients
with active TB than in cells of patients with latent M. tuberculosisses. Published by Elsevier Ltd. All rights reserved.
Table 1
Indication (therapeutic vs. diagnostic) and main clinical pathology when therapeutic.
Subject Sex Age Chest CT TSTa Sputum MTB Clinical feature Anti-TB drug
therapy (years)
Resection type
Smear Culture Fever Cough (years) Hemoptysis
1 M 29 (1) Type III TB;
(2) RLL cavity
concurrent infection
+++ +++ + 37.5–39.0 8C Cough 3 years intermittently  2.5 Wedge resection
2 M 53 (1) Type III TB;
(2) LUL cavity
++ ++ + 37.3–38.8 8C Cough 7 years intermittently + 6 Wedge resection
3 M 18 (1) Type III TB;
(2) LUL cavity
concurrent infection
+++ + + 37.0–39.0 8C Cough 1.5 years intermittently  1 Lobectomy
4 M 53 (1) Type III TB;
(2) RUL cavity concurrent
aspergilloma
++  + 37.5–38.5 8C Cough 5 years intermittently  4.5 Lobectomy
5 M 70 (1) Type III TB;
(2) RUL cavity concurrent
aspergilloma
++ + + 37.2–38.6 8C Cough 6 years intermittently + 5.5 Lobectomy
6 M 42 (1) Type III TB;
(2) RLL cavity concurrent
aspergilloma
++ + + 37.5–39.5 8C Cough 10 years intermittently + 7 Lobectomy
7 F 59 (1) Type III TB;
(2) RUL cavity
concurrent infection
++ + + 37.5–39.0 8C Cough 20 years intermittently + 7 Lobectomy
8 F 52 (1) Type III TB;
(2) LUL cavity concurrent
aspergilloma
++  + 37.2–38.5 8C Cough 5 years intermittently + 3.5 Wedge resection
9 M 57 (1) Type III TB;
(2) LUL cavity
concurrent infection
++ + + 37.5–39.5 8C Cough 4 years intermittently  3 Lobectomy
10 M 53 (1) Type III TB;
(2) RUL cavity concurrent
aspergilloma; (3) RCW abscess
++ + + 37.2–39.5 8C Cough 3.5 years intermittently  3 Lobectomy
11 F 51 (1) Type III TB;
(2) RL destroyed
++ + + 37.4–39.6 8C Cough 20 years intermittently + 15 Pulmonary resection
12 M 49 (1) Type III TB;
(2) LL destroyed
+++ ++ + 37.6–38.9 8C Cough 7 years intermittently + 5.5 Pulmonary resection
13 F 62 (1) Type III TB;
(2) LUL cavity concurrent
aspergilloma; (3) RCW abscess
++ + + 37.2–38.9 8C Cough 11 years intermittently  9.5 Lobectomy
CT, computerized tomographic scanning; TST, tuberculin skin test; MTB,Mycobacterium tuberculosis; TB, tuberculosis; RLL, right lower lobe; LUL, left upper lobe; RUL, right upper lobe; RCW, right chest wall; RL, right lobe; LL, left
lobe.
a TST (PPD 5 U 0.1ml, measure the red spot after 72h): negative : <5mm; positive +: 5–9mm; ++: 10–19mm; +++: 20mm.
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Table 2
Bacterial susceptibility test results of patients preoperatively.
Subject Sex Age Susceptibility test results
SM INH RFP EMB LVX D CTH-1321 CPM
1 M 29 R R R R S S S S
2 M 53 S R R S R R S S
3 M 18 S R R S S S S S
4 M 53 R R R R R S S S
5 M 70 S R R S R R S S
6 M 42 R S R S S S S S
7 F 59 R R S S S S S S
8 F 52 S R S R S S S S
9 M 57 R R R R S S S S
10 M 53 R R R S R S S S
11 F 51 R R R R R R S S
12 M 49 R R R R R S S S
13 F 62 S R R S S S S S
SM, streptomycin; INH, isoniazid ; RFP, rifampin; EMB, ethambutol; LVX, levoﬂoxacin ; D, dipasic (pasiniazid); CTH-1321, prothionamide; CPM, capreomycin; R, resistant; S,
sensitive.
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CD4+CD25high FoxP3+ cells is not increased,11 nor is the proportion
of CD4+CD25high T cells decreased12 ex vivo in patients with active
TB disease.
Because immunopathology is thought to play amajor role in the
pathogenesis of active TB, CD4+CD25high Treg cells are considered
part of the regulatory mechanisms of immunity on invasion by M.
tuberculosis. Thus, we aimed to determine whether elevated Treg
cell numbers may be decreased after pulmonary resection in
patients with pulmonary MDR-TB and found that the relative
increase in Treg cell ratios is signiﬁcantly decreased after
pulmonary resection.
2. Methods
2.1. Patients and controls
Between January 2006 and December 2008, we enrolled 13
patients (nine men; mean age 50 years, range 18–70 years)
undergoing surgery for pulmonary tuberculosis at The ThirdTable 3
Main clinical symptom status of patients at postoperative month 6.
Subject Sex Age Chest CT (comparison with preoperative) Sputum
Smear
1 M 29 RLL cavity removal 
2 M 53 LUL cavity removal 
3 M 18 LUL cavity removal 
4 M 53 RUL cavity and aspergilloma removal,
residue intrapulmonary air containing
space with thick wall

5 M 70 RUL cavity and aspergilloma removal,
residue intrapulmonary air containing
space with thick wall

6 M 42 RLL cavity and aspergilloma removal,
residue intrapulmonary air containing
space with thick wall

7 F 59 RUL cavity removal 
8 F 52 LUL cavity and aspergilloma removal 
9 M 57 LUL cavity removal 
10 M 53 RUL cavity and aspergilloma, and RCW
abscess removal, pleura thickening

11 F 51 RL removal, residue intrapulmonary air
containing space with thick wall

12 M 49 LL removal, residue intrapulmonary air
containing space with thick wall

13 F 62 LUL cavity and aspergilloma and RCW
abscess removal, pleura thickening

CT, computerized tomographic scanning; MTB,Mycobacterium tuberculosis; RLL, right low
lobe; LL, left lobe; NE, no examination; NR, no record.People’s Hospital of Shantou City. These patients exhibited cavity
MDR-TB concurrent infection (n = 5), cavity MDR-TB concurrent
aspergilloma (n = 6), or lung destruction (n = 2). The mean time
with anti-tubercular drug therapy was 5.6 years (range 1–15
years). The indication (therapeutic vs. diagnostic) and the main
clinical pathologies are shown in Table 1. Results of bacterial
susceptibility testing are shown in Table 2. The main clinical
symptom status of patients at postoperative month 6 (POM6) is
shown in Table 3. In subject 4, the right upper lobe cavity showed
concurrent aspergilloma (Figure 1, A1–A4), and the patient
underwent lobectomy of the right lung in October 2008. Subject
11 showed a destroyed right lobe and underwent pulmonary
resection in September 2006 (Figure 2, B1–B5).
Peripheral blood was obtained from patients before and 1 and 6
months after surgery. We recruited 10 healthy volunteers (seven
men; mean age 42 years, range 25–63 years). All patients
underwent postoperative individualized chemotherapy to ensure
long-term cure. All subjects were HIV-negative. The study protocol
was approved by our institutional review board for human studies,
and informed consent was obtained from all subjects.MTB Clinical features
Culture Body temperature Cough Hemoptysis
 36.9 8C No cough 
 36.7 8C Cough occasionally 
NE 36.8 8C No cough 
 36.7 8C Cough intermittently 
NE 36.5 8C Cough occasionally 
NE 36.9 8C NR 
NE 36.4 8C Cough occasionally 
 36.5 8C Cough occasionally 
 36.8 8C Cough occasionally 
NE 36.5 8C Cough intermittently 
 36.8 8C Cough intermittently 
NE 36.8 8C Cough intermittently 
 36.5 8C Cough intermittently 
er lobe; LUL, left upper lobe; RUL, right upper lobe, RCW, right chest wall; RL, right
[(Figure_1)TD$FIG]
Figure 1. Computed tomography (CT) scan of a 53-year-oldmanwithmultidrug-resistant tuberculosis. Preoperative CT scan of the chest in October 2008 (A1, A2): right upper
lung cavity shows concurrent aspergilloma. Postoperative CT scan of the chest in April 2009 (postoperative month 6: A3, A4): focus of infection was removed and residual
intrapulmonary air-containing space with thick wall.
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Whole blood was collected in 12 75-mm plastic tubes
containing anti-coagulant (EDTA-K2) and immediately underwent
cellular staining. Whole blood (100ml) was aliquoted (per tube)
along with 20ml of appropriate test antibody or respective isotype
control for three color tests: ﬂuorescein isothiocyanate (FITC) anti-
FoxP3 (clone PCH101, CAT.11-4766, eBioscience, San Diego, CA,
USA), phycoerythrin peridinin chlorophyll protein (PerCP) anti-CD4
(clone RPA-T4, CAT.300528, Biolegend, San Diego, CA, USA), and
phycoerythrin (PE) anti-CD25 (clone B1.49.9, CAT.IM0479u, Beck-
man Coulter, Los Angeles, CA, USA). The following isotype control
antibodies were used: FITC rat IgG2b (k, CAT.11-4031, eBioscience),
PerCP mouse IgG1 (clone MOPC-21, CAT.400145, Biolegend), PE
mouse IgG1 (clone 679.1 Mc7, CAT.IM0670u, Beckman Coulter).
After surface staining for 30 min in the dark at room temperature,
erythrocytes were lysed, and cells were ﬁxed with the use of
immuno-prep reagents (Beckman Coulter) using a Q-prep Immu-
nology workstation (Beckman Coulter). Surface-stained cells then[(Figure_2)TD$FIG]Figure 2. Computed tomography (CT) scan of a 51-year-old female with multidrug-resis
right lung destroyed and collapsed, the left lung showing scale-up complications. Postop
infection was removed and residual intrapulmonary air-containing space with thick wunderwent intracellular FoxP3 staining with use of the anti-FoxP3
staining kit according to the manufacturer’s recommendations.
2.3. Data acquisition and analysis
Listmode data were acquired on the Epics XL ﬂow cytometer
(Beckman Coulter) and were analyzed using EXPO32 software
(Beckman Coulter). The lymphocyte gate was generated by use of
forward and side-angle scattered (FSC/SSC) light window leuko-
gating to analyze the cell-surface antigens CD4 and CD25. To
determine the proportion of Treg cells, CD4
+ T cells were gated by
plotting forward versus side scatter to analyze the intracytoplasm
antigen against FoxP3.
2.4. Statistical analysis
Values are presented as mean  standard deviation (SD). All
results were analyzed using SPSS v 13.0 (SPSS Inc., Chicago, IL, USA).
Differences inmeans between patients and controlswere analyzed bytant tuberculosis. Preoperative CT scan of the chest in September 2006 (B1, B2, B3):
erative CT scan of the chest in May 2007 (postoperative month 6: B4, B5): focus of
all.
[(Figure_4)TD$FIG]Y.E. Wu et al. / International Journal of Infectious Diseases 14 (2010) e815–e822 e819one-way analysis of variance (ANOVA); differences in means for
patients pre- and postoperativelywere analyzed by paired-samples t-
test and correlation was examined by Spearman rank correlation
analysis. A p-value of <0.05 was considered statistically signiﬁcant.
3. Results
To determine the frequency of Treg cells, gated lymphocytes
and CD4+ cells were analyzed for expression of CD4, CD25Figure 4. Flowcytometry analysis of intracellular FoxP3 and surfaceCD25 expression
on CD4+ T cells in patients with tuberculosis (TB). The CD4+ T cells are shown gated
(A2). Representative ﬂow cytometry results of intracellular FoxP3 and surface CD25
expression on peripheral blood lymphocytes from a patient with active TB
preoperatively (B2), at postoperative month 1 (POM1; C2), and at postoperative
month 6 (POM6; D2). G1:CD4+CD25+FoxP3 cells; G2:CD4+CD25+FoxP3+ cells;
G3:CD4+CD25 FoxP3 cells; G4:CD4+CD25 FoxP3+ cells.
[(Figure_3)TD$FIG]
Figure 3. Flow cytometry analyses of CD25+high expression by CD4+ T cells. The
lymphocyte gate was generated by use of forward and side-angle scattered light
window (FSC/SSC) dot plots (A1). Representative ﬂow cytometry results of surface
CD4 and CD25 expression on peripheral blood lymphocytes from a patient with
active TB preoperatively (B1), at postoperative month 1 (POM1; C1), and at
postoperative month 6 (POM6; D1). L1: CD4CD25+ cells; L2: CD4+CD25+ cells; L3:
CD4CD25 cells; L4: CD4CD25+ cells; M1: CD4CD25+high cells; M2:
CD4+CD25+high cells; M3: CD4CD25high cells; M4: CD4CD25+ cells.
[(Figure_5)TD$FIG]
Figure 5. Percentage of CD4+ cells, CD4+CD25+ cells, and CD4+CD25 cells in non-
infected control subjects (CTRL; n = 10), and in patientswith cavityMDR-TB (n = 13)
pre- and postoperatively: preoperative, postoperative month 1 (POM1), and
postoperative month 6 (POM6).
Y.E. Wu et al. / International Journal of Infectious Diseases 14 (2010) e815–e822820(representative plots in Figure 3, A1–D1), and FoxP3 (representa-
tive plots in Figure 4, A2–D2).
3.1. Phenotypic analysis of CD4+ cells in patients with cavity MDR-TB
pre- and postoperatively
On ﬂow cytometry, as comparedwith healthy controls, patients
with MDR-TB showed signiﬁcantly decreased proportions of CD4+
T cells preoperatively (31.85  1.03% vs. 38.91  2.10%); this was
increased postoperatively compared with preoperatively (postoper-
ative month 1 (POM1) 39.59  2.26%, postoperative month 6 (POM6)
39.02  1.47%) (p < 0.001). Also, the proportion of CD4+CD25+ cells
was signiﬁcantly increased preoperatively (12.28  1.96% vs.
8.36  1.54% for controls) and decreased postoperatively compared
with preoperatively (POM1 9.91  1.50%, POM6 9.23  0.78%)
(p < 0.001). However, the proportion of CD4+CD25 cells was
signiﬁcantly decreased preoperatively (19.56  2.78% vs.
30.55  2.82% for controls) and increased postoperatively compared
with preoperatively (POM1 29.68  3.26%, POM6 29.78  1.56%)
(p < 0.001) (Figure 5).
[(Figure_6)TD$FIG]
Figure 6. The proportion of CD4+CD25+ cells that are CD25high in non-infected controls
preoperative, postoperative month 1 (POM1), and postoperative month 6 (POM6). Hor3.2. The frequency of CD4+CD25high Treg cells was increased in patients
with cavity MDR-TB before surgery
The frequency of CD4+CD25high Treg cells was determined on
ﬂow cytometry. The lymphocytes were gated to analyze
CD4+CD25high Treg cells. As compared with controls, patients with
MDR-TB showed signiﬁcantly increased proportions of
CD4+CD25high Treg cells both preoperatively and at 1-month
postoperatively (7.00  1.10%, POM1 6.25  1.23% vs. 4.16  1.02%
for controls) (p < 0.001), with no signiﬁcant increase in proportion of
CD4+CD25high Treg cells at 6-months postoperatively compared with
healthy controls (p > 0.05) (Figure 6).
3.3. The proportion of CD25+FoxP3+ Treg cells in CD4
+ cells was high in
patients preoperatively
Since FoxP3 transcription factor is considered the most reliable
molecular marker of CD4+CD25high Treg cells, we investigated the
intracellular expression of FoxP3 in CD4+CD25+ T cells. FoxP3
expression was signiﬁcantly higher in patients preoperatively and
at 1-month postoperatively as compared with healthy controls
(7.45  1.19%, POM1 6.74  1.03% vs. 4.50  1.03%) (p < 0.001).
However, at 6-months postoperatively, the proportion of
CD4+CD25+FoxP3+ Treg cells was similar between healthy subjects
and patients (p > 0.05) (Figure 7).
3.4. The proportion of CD4+CD25high and CD4+CD25+FoxP3+ Treg cells
decreased at 6-months postoperatively
We investigated the proportion of CD4+CD25high and
CD4+CD25+FoxP3+ Treg cells pre- and postoperatively. The propor-
tion of both CD4+CD25high and CD4+CD25+FoxP3+ Treg cells in
patients with TB was signiﬁcantly lower at 6-months postopera-
tively than preoperatively (p < 0.001), with no signiﬁcant differ-
ence between preoperative and 1-month postoperative
proportions (p > 0.05) (Figures 8 and 9).
3.5. Correlation between the expression of CD4+CD25high cells and
CD4+CD25+FoxP3+ cells in MDR-TB patients
We analyzed the correlation between the proportion of
CD4+CD25high and CD4+CD25+FoxP3+ cells in peripheral blood in
patients with active cavity MDR-TB and found a signiﬁcant(CTRL; n = 10) and patients with cavity MDR-TB before and after surgery (n = 13):
izontal bars indicate median values.
[(Figure_7)TD$FIG]
Figure 7. The proportion of CD4+CD25+FoxP3+ Treg cells among the CD4
+ cells measured by ﬂow cytometry in 10 non-infected control subjects (CTRL) and 13 patients with
cavity MDR-TB pre- and postoperatively: preoperative, postoperative month 1 (POM1), and postoperative month 6 (POM6). Horizontal bars indicate median values.
[(Figure_9)TD$FIG]
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(Figure 10).
4. Discussion
The estimated worldwide incidence of TB and MDR-TB
continues to increase. Despite the success of medical therapy
alone, resistance to drugs and complications of the disease still
present a challenge.13 The host response to infection with M.
tuberculosis involves the cellular immune system of T-helper 1-
type interferon-g-secreting CD4 and CD8 effector T cells.14 This
[(Figure_8)TD$FIG]Figure 8. The proportion of the CD4+CD25+ cells that are CD25high in patients with
cavity MDR-TB pre- and postoperatively (n = 13): preoperative, postoperative
month 1 (POM1), and postoperative month 6 (POM6).response helps to limit bacterial replication and dissemination in
vivo and causes important immunopathologic features such as
inﬂammation, but in general fails to eradicate the infection. We
suggested that the immune system has regulatory mechanisms to
suppress the effector response to persistent antigens. Indeed, we
found the proportion of CD4+CD25high and CD4+CD25+FoxP3+ Treg
cells signiﬁcantly higher in patients with cavity MDR-TB and at 1-
month postoperatively than in healthy controls. Also, theFigure 9. The proportion of the CD4+CD25+FoxP3+cells in patients with cavityMDR-
TB pre- and postoperatively (n = 13): preoperative, postoperative month 1 (POM1),
and postoperative month 6 (POM6).
[(Figure_10)TD$FIG]
Figure 10. Correlation between the proportion of CD4+CD25+high cells and
CD4+CD25+FoxP3+ cells (r = 0.878, p < 0.001).
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patients with cavity MDR-TB than in healthy controls.
Increasingly, FoxP3-expressing Treg cells are considered critical
for suppressing immune responses to self-antigens and preventing
autoimmunity and for regulating immunity to foreign antigens,
especially those derived from pathogens that establish persistent
infections.15 Treg cells were found to prevent eradication of
tubercle bacilli by suppressing an otherwise efﬁcient CD4+ T-cell
response.16 To investigate Treg cells, we used themarkers CD4
+ and
high levels of cell-surface CD25 expression and intracellular FoxP3
expression. The expression of CD4+CD25high cells and
CD4+CD25+FoxP3+ cells was signiﬁcantly increased in peripheral
blood of patients with cavity MDR-TB, which is in agreement with
the report by Guyot-Revol et al.9 Previously, the proportion of
CD4+CD25high T cells and CD4+CD25high FoxP3 cells was found
signiﬁcantly higher in PBMCs of patients with active TB as
comparedwith thosewith latent TB infection and controls, with no
difference between those with latent infection and healthy
controls.10 However, whether Treg cells decreased in number after
cure of active TB was unknown. Therefore, we analyzed the
expression of CD4+CD25high cells and CD4+CD25+FoxP3+ cells at 1
and 6 months after surgery in patients with cavity MDR-TB. The
proportion of CD4+CD25high cells and CD4+CD25+FoxP3+ cells was
signiﬁcantly decreased in peripheral blood at 6-months postoper-
atively as compared with preoperatively and 1-month postopera-
tively, and did not signiﬁcantly differ from that in healthy controls.
One possible mechanism for Treg cells suppressing anti-M.
tuberculosis immunity is that CD4+CD25+FoxP3+ regulatory T cells
produce the cytokine TGF-b and/or IL-10, which depresses
interferon-gamma (IFN-g) production.17 Neutralization of TGF-b
and IL-10 each result in an increase in elicited IFN-g.18
CD4+CD25+FoxP3+ Treg expansion in TB patients may contribute
to suppress M. tuberculosis immune responses by inhibiting IFN-g
production of PBMCs in patients with active TB or pleural ﬂuid
mononuclear cells in patients with tuberculous pleurisy.19
However, the mechanisms by which Treg cells increase in number
are incompletely understood and need further research. The
bacterial burden may, in part, induce the increase in Treg cells.
MDR-TB is caused byM. tuberculosis strains resistant to at least
rifampin and isoniazid. Because failure of medical treatment leads
to a dismal prognosis, surgical resection has been advocated to
supplement medical therapy in some patients with tracheal or
bronchial stenosis, aspergillomas growing on cavitated lesions,bronchiectasis, destroyed lungs, or massive hemoptysis. Our
patients showed a good prognosis after surgery, which suggests
that the immunity function recovered after surgery. Because
morbidity andmortality rates are acceptable, surgical intervention
can be considered safe and effective in patientswith pulmonary TB.
Conﬂict of interest
No conﬂict of interest to declare.
Acknowledgements
This study was supported by the 211 Project of Guangdong
Province (Mechanism and Prevention of New Emergence Infection)
and the Science and Technology Planning Project of Shantou
(Prognostic Evaluation of Pulmonary Resection in the Treatment of
Cavity Multidrug-resistant Tuberculosis (2009–70)), Guangdong
Province, China.
References
1. World Health Organization. WHO report 2009. Global tuberculosis control—
epidemiology, strategy, ﬁnancing. WHO/HTM/TB/2009.411. Geneva: WHO;
2009. Available at: http://www.who.int/tb/publications/global_report/2009/
key_points/en/index.html.
2. World Health Organization. Anti-tuberculosis drug resistance in the world.
WHO/HTM/TB/2008.394. Geneva: WHO; 2008. Available at: http://whqlibdoc.
who.int/hq/2008/WHO_HTM_TB_2008.394_eng.pdf.
3. Pomerantz BJ, Cleveland JC, Olson HK, Pomerantz M. Pulmonary resection for
multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 2001; 108:448-53.
4. Furak J, Trojan I, Szoke T, Tiszlavicz L, Morvay Z, Csada E, et al. Surgical
intervention for pulmonary tuberculosis: analysis of indications and perioper-
ative data relating to diagnostic and therapeutic resections. Eur J Cardiothorac
Surg 2001; 20:722-7.
5. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93–
129.
6. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-
tolerance and negative control of immune responses. Annu Rev Immunol
2004;22:531–62.
7. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the
transcription factor FoxP3. Science 2003;299:1057–61.
8. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol
2005;6:338–44.
9. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are
expanded in blood and disease sites in tuberculosis patients. Am J Respir Crit
Care Med 2006;173:803–10.
10. Hougardy JM, Place S, Hildebrand M, Drowart A, Debrie AS, Locht C, Mascart F.
Regulatory T cells depress immune responses to protective antigens in active
tuberculosis. Am J Respir Crit Care Med 2007;176:409–16.
11. Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, Girard E, et al. Characteri-
zation of regulatory T cells identiﬁed as CD4+CD25highCD39+ in patients with
active tuberculosis. Clin Exp Immunol 2009; 156:463-70.
12. Roberts T, Beyers N, Aguirre A, Walzl G. Immunosuppression during active
tuberculosis is characterized by decreased interferon-g production and CD25
expression with elevated forkhead box P3, transforming growth factor-b, and
interleukin-4 mRNA levels. J Infect Dis 2007; 195:870-8.
13. Souilamas R, Riquet M, Barthes FP, Chehab A, Capuani A, Faure E. Surgical
treatment of active and sequelar forms of pulmonary tuberculosis. Ann Thorac
Surg 2001; 71:443-7.
14. Stenger S, Modlin RL. T cell mediated immunity to Mycobacterium tuberculosis.
Curr Opin Microbiol 1999;2:89–93.
15. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat
Immunol 2005;6:353–60.
16. Mischo K, Markus K, Hans-Willi M, Nouailles G, Bonhagen K, Kamrad T, et al.
Regulatory T cells prevent efﬁcient clearance of Mycobacterium tuberculosis. J
Immunol 2007; 178:2661-5.
17. Ribeiro-Rodrigues R, Resende Co T, Rojas R, Toossi Z, Dietze R, BoomWH, et al. A
role for CD4+CD25+ T cells in regulation of the immune response during human
tuberculosis. Clin Exp Immunol 2006;144:25–34.
18. Mason CM, Porretta E, Zhang P, Nelson S. CD4+ CD25+ transforming growth
factor-b-producing T cells are present in the lung in murine tuberculosis and
may regulate the host inﬂammatory response. Clin Exp Immunol 2007;
148:537-45.
19. Chen XC, Zhou BP, Li MZ, Deng QY, Wu XQ, Le XH, et al. CD4+CD25+FoxP3+
regulatory T cells suppress Mycobacterium tuberculosis immunity in patients
with active disease. Clin Immunol 2007; 123:50-9.
